Publication
Response to Comment on: "Is it time to reduce the doxorubicin dosage in Hodgkin lymphoma therapy?".
Eldad J Dann
HaematologicaSep 1, 2026PMID 42206426doi:10.3324/haematol.2026.301249 PMC13530946Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260908-000002
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerHodgkin Lymphomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.